The number of very early thus right censored patients in the bavi's 3mg arm would be my major concern at this moment.
Those must be lost to follow ups given the time from end of enrollment in Oct of last year to the survival analysis done presumably in late May-June. By my count the first 6 months on the OS plot has 8 LTFUs total for the combined Bavi arms and 1 on the control arm. It's curious to have such a large imbalance for a drug with apparently no side effects.
Market Data 
Markets 
AI
